Diabetes Distress

Hosted by Nancy Hanna and Dena Gottesman

The guest on this episode has an ongoing commercial relationship with Insulet, and Insulet has paid a fee for their participation in this podcast.

Recorded live at the ADCES Conference in Houston, Nancy Hanna and Dena Gottesman are joined by Dr. William Polonsky. Dr. Polonsky is the founder and president of the Behavioral Diabetes Institute, an organization dedicated to studying the unmet psychological needs of people living with diabetes. He’s also an Associate Clinical Professor at the University of California in San Diego. 

Highlights include:

  • How the world’s first behavioral diabetes institute was formed. 
  • The origin and meaning of the term “Diabetes Distress” and strategies to communicate effectively with patients and ease burden
  • Psychosocial outcomes with Omnipod 5 and impact on caregivers 

Time stamps

11:34 – Understanding and recognizing Diabetes Distress
16:52 – Learn about Omnipod’s published psychosocial outcomes.
34:33 – Hear how Omnipod 5 has improved the lives of Dr. Polonsky’s patients

 

See more episodes
This podcast provides general information and discussions about health and related subjects. This information and other content provided in this podcast, or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. If you or any other person has a medical concern, you should consult your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that you have heard in this podcast or read in any linked materials. The opinions and views expressed on this podcast and website have no relation to those of any academic, hospital, health practice or other institution.

Please consult the Omnipod® 5 Automated Insulin Delivery System User Guide for more information.

The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older & type 2 diabetes in persons aged 18 years and older. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®, Humalog®, and Admelog®. Refer to the Omnipod 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions. Warning: DO NOT use SmartAdjust technology for individuals under 2 years of age or use less than 5 U of insulin per day. DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.